AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03910127
Drug: TQB2450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Trial: NCT01253434
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2022 Type A patch
Trial: NCT01253434
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2022 Type B patch
Trial: NCT01253434
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2022 Type C patch
Trial: NCT01253434
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2022 Type D patch
Trial: NCT01253434
Drug: E2022
RxNorm normalized name: LARYNGEAL PROSTHESIS,BLOM-SINGER BE2022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2022 Type E patch
Trial: NCT00690521
Drug: Treatment of Furosemide + Hydrochlorothiazide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A randomized, double-blind, crossover study designed to compare the efficacy of hydrochlorothiazide in combination with stable doses of furosemide in congestive heart failure patients.
Trial: NCT04321252
Drug: KAE609
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)
Trial: NCT04321252
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placeo for iv administration
Trial: NCT01426399
Drug: LC15-0444
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LC15-0444 50mg qd (8 days once daily)
Trial: NCT02848417
Drug: Glutathione
RxNorm normalized name: Glutathione
DrugBank: Glutathione (DB00143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
Trial: NCT01211626
Drug: ANA773
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ANA773 Tosylate Capsule
Trial: NCT01211626
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Capsule
Trial: NCT00139750
Drug: CP-526,555 (varenicline)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01458574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mg orally (PO) twice a day (BID)
Trial: NCT01458574
Drug: CP690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 5 mg orally (PO) twice a day (BID)
Trial: NCT01458574
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 10 mg orally (PO) twice a day (BID)
Trial: NCT02506296
Drug: DPPIV inhibitor -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed Meal Tolerance Test with or without a DPPIV inhibitor
Trial: NCT01951235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03164512
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule/vapor
Trial: NCT04032171
Drug: Avonex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received avonex® IM injection once a week.
Trial: NCT04032171
Drug: Avonex® matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received IM injection of placebo matched to avonex® once a week.
Trial: NCT00747799
Drug: Sorafenib plus Cisplatin and 5-fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)~* Sorafenib 400 mg bid per daily . Every 21-day cycles.~* Cisplatin 80 mg/m2 day d1, every 21 days cycle.~* 5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles
Trial: NCT00497653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, twice daily for 6 weeks
Trial: NCT00424437
Drug: Inhaled human insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03743038
Drug: FMX101 vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)
Trial: NCT00411567
Drug: inhaled corticosteroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03843918
Drug: LAE001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAE001 BID will be orally administered until the subjects develop disease progression, intolerable adverse events, or trial withdrawal decided by the investigator/subject. The LAE001 dose adopted for the phase II study will be based on the RP2D determined in the phase I study.
Trial: NCT02302079
Drug: ASP8232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT02302079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT01503905
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m2, iv injection, day1, every 21 days
Trial: NCT01069523
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
Trial: NCT03820037
Drug: BIA 9-1067 (test)
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral 50 mg (capsule containing 50 mg OPC) under fasting conditions
Trial: NCT02504476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01503905
Drug: Cyclophosphamide (post-operative)
RxNorm normalized name: Sx1 Medicated Post-Operative System KIT
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
Trial: NCT01503905
Drug: Herceptin （post-operative)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
Trial: NCT02276482
Drug: Antibiotic comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic comparator drug, IV and/or orally for 10 days. Antibiotic comparator included the following: Vancomycin, Linezolid, Clindamycin, Flucloxacillin, Cefazolin, Cephalexin.
Trial: NCT00347555
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
Trial: NCT00536978
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg IV Daily Over 30 Minutes for 3 Days
Trial: NCT00536978
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 IV Daily Over 1 Hour for 3 Days
Trial: NCT00536978
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 IV on Days +1, +3, and +6.
Trial: NCT02403193
Drug: PBF-509_320 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBF-509: 320 mg, PO, twice daily (BID)
Trial: NCT02403193
Drug: PBF-509_640 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PBF-509: 640 mg, PO, twice daily (BID)
Trial: NCT02403193
Drug: Combo PBF-509 (160 mg) + PDR001
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Trial: NCT02403193
Drug: Combo PBF-509 (320 mg) + PDR001
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Trial: NCT02403193
Drug: Combo PBF-509 (640 mg) + PDR001
RxNorm normalized name: NexGard Combo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
Trial: NCT02403193
Drug: RP2D (PBF-509+PDR001)_immuno naïve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Trial: NCT02403193
Drug: Experimental: RP2D (PBF-509+PDR001)_immuno treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
Trial: NCT02638805
Drug: ITCA 650 Osmotic Mini Pump 20/60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
Trial: NCT02638805
Drug: ITCA 650 Osmotic Mini Pump 60 mcg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
Trial: NCT03699631
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate will be administered at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic cell infusion.
Trial: NCT02267382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01165281
Drug: R331333 (referred to as JNS024 ER or CG5503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 25 mg to 200 mg capsule twice daily for 4 weeks.
Trial: NCT02863991
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 375 mg or 625 mg ONC201
Trial: NCT00558285
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
Trial: NCT00337766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02730819
Drug: Illuminate Cream
RxNorm normalized name: bismuth aluminate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical compound applied daily
Trial: NCT01674036
Drug: Genz-682452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT01674036
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Genz-682452
Trial: NCT03483636
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated oral tablet
Trial: NCT00901290
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mg, oral dose
Trial: NCT03143218
Drug: SMC placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Year 1, 2 and 3(2017/18/19) Four cycles of SMC placebo during the malaria transmission season
Trial: NCT02099006
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To be applied topically at a 10% concentration
Trial: NCT02099006
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounding base to be used alone as a placebo
Trial: NCT03103555
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
Trial: NCT00808249
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets taken twice a day for 28 days
Trial: NCT00808249
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets taken twice a day for 28 days
Trial: NCT01887249
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04413890
Drug: Dinoprostone vaginal gel
RxNorm normalized name: dinoprostone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prostaglandin gel 0.5, 1 or 2 mg
Trial: NCT02537379
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablets administered orally once daily
Trial: NCT02087384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of 0.9% saline
Trial: NCT03179514
Drug: Anti-Platelet Drugs
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Including aspirin and clopidogrel, etc.
Trial: NCT03179514
Drug: Lipid Regulating Drugs
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including statins
Trial: NCT03179514
Drug: Coronary Vasodilator
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including nitrates
Trial: NCT03179514
Drug: Gualou Xiebai Banxia Decoction & Danshen Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Trial: NCT02045212
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection twice a week during 13/26 weeks
Trial: NCT02128763
Drug: Omega-3 supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2000 mg EPA and 1000 mg DHA per day
Trial: NCT02128763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
Trial: NCT02357849
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: see arm description
Trial: NCT01758666
Drug: Methotrexate,Calcium folinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00504335
Drug: BIO 300 Capsules
RxNorm normalized name: Bio-Kool
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03641209
Drug: Paracetamol 10mg/mL infusion solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol solution for infusion
Trial: NCT01586156
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be taken twice daily for 6 months
Trial: NCT00547378
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
Trial: NCT00815906
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, Single dose
Trial: NCT00815906
Drug: SBI-087
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC, Single dose
Trial: NCT03148431
Drug: LY3002815
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT03148431
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV
Trial: NCT01360944
Drug: reference
RxNorm normalized name: Loreal Preference Dark Auburn 4R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily, 100 microgram
Trial: NCT02591654
Drug: FLT PET
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
Trial: NCT04198662
Drug: Intercostal nerve block ropivacaine with epinephrine
RxNorm normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
Trial: NCT04198662
Drug: Placebo intercostal nerve block with normal saline
RxNorm normalized name: ACS22Q55 NERVE BLOCK KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
Trial: NCT03701750
Drug: Low Molecular Weight Heparin (enoxaparin sodium)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
Trial: NCT00016133
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00016133
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02081300
Drug: Oral testosterone undecanoate, LPCN 1021
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02081300
Drug: Topical testosterone gel 1.62 %
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04419493
Drug: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)
Trial: NCT00587873
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
Trial: NCT00587873
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
Trial: NCT02896907
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02896907
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00970502
Drug: erlotinib + celecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
Trial: NCT04486963
Drug: Sanhuangjingshimingwan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.
Trial: NCT00625521
Drug: Cream vehicle for ASF 1096 cream applied twice daily
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01760993
Drug: SPD489
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
Trial: NCT03056495
Drug: N-hydroxy-N'-phenyl-octanediamide (Vorinostat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
Trial: NCT03754062
Drug: Placebo - Cap
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of Placebo by pill.
Trial: NCT00731263
Drug: AZD8055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
Trial: NCT00180141
Drug: Elidel-Creme
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02233400
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
Trial: NCT01833767
Drug: Cyclophosphamide and Interleukin 2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cytoxan IV day 1, IL2 IV days 1-5
Trial: NCT03656120
Drug: 0.2mg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienorphine hydrochloride dose was set as 0.2mg per day,last for 12 weeks.
Trial: NCT03656120
Drug: 0.5mg group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienorphine hydrochloride dose was set as 0.2mg per day for the first week and increased to 0.5mg per day from the second week, last for 11 weeks.
Trial: NCT03656120
Drug: placebo control group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants only take placebos for 12 weeks during the research.
Trial: NCT02012608
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For subjects undergoing breast conserving therapy